Where Will Graybug Vision Inc (GRAY) Stock Go Next After It Has Risen 15.31% in a Week?

Monday, July 11, 2022 12:46 PM | InvestorsObserver Analysts

Mentioned in this article

Where Will Graybug Vision Inc (GRAY) Stock Go Next After It Has Risen 15.31% in a Week?

Graybug Vision Inc (GRAY) stock has gained 15.31% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Graybug Vision Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GRAY!

See Full GRAY Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With GRAY Stock Today?

Graybug Vision Inc (GRAY) stock is trading at $1.13 as of 12:12 PM on Monday, Jul 11, a decline of -$0.05, or -4.24% from the previous closing price of $1.18. The stock has traded between $1.10 and $1.18 so far today. Volume today is below average. So far 47,851 shares have traded compared to average volume of 613,998 shares.

More About Graybug Vision Inc

Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company's products under pipeline are GB-102, for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME; GB-103; and GB-401. Click Here to get the full Stock Report for Graybug Vision Inc stock.